Drug Regulation, Treatment, and Public Order

Start from the harms

“Drugs” is not one policy category. Cannabis, alcohol, nicotine, fentanyl, methamphetamine, prescribed opioids, psilocybin, and an adulterated street pill differ in lethality, dependence, medical use, route, market, and third-party effect. Personal possession, public intoxication, impaired driving, commercial sale, predatory dealing, and violent trafficking are different acts. A law that collapses them can be both cruel and ineffective.

The Innovation Party starts from five harms: overdose and poisoning; addiction and impaired agency; violence and predatory markets; danger imposed on other people; and public spaces made unusable by persistent conduct. It also recognizes harms created by policy: criminal records, incarceration, family disruption, unsafe unregulated supply, reluctance to call for help, barriers to treatment, and enforcement that varies by race, place, and wealth.

The policy question is which tool reduces total harm while respecting adult autonomy, public order, and scientific uncertainty. Legal regulation is appropriate for adult cannabis. Health-centered decriminalization is appropriate for possession of small quantities of other drugs. Treatment and overdose response are appropriate for addiction. Criminal enforcement remains appropriate for predation, lethal commerce, violence, minors, impaired operation, and persistent harmful conduct.

Regulate adult cannabis nationally

Federal law should remove cannabis from the Controlled Substances Act rather than leave a state- legal industry inside federal prohibition or merely transfer cannabis to Schedule III. In July 2026, federal rescheduling proceedings were still underway. Rescheduling may recognize accepted medical use and reduce some tax and research burdens. It would not create a coherent legal adult- use market or erase the conflict between federal prohibition and state authorization.

Congress should establish a regulatory framework analogous in function, though not identical, to alcohol, tobacco, food, and medicine. Adults 21 and older may purchase from licensed businesses in states that permit sale. States may prohibit commercial sale, operate public or nonprofit models, limit outlets, or set stronger product rules. Interstate commerce should begin only after federal and participating-state systems can track lawful product, test safety, collect tax, and prevent diversion.

Products should disclose active ingredients, dose or serving, ingredients, contaminants, and a standard health warning in plain language. Inhaled, edible, concentrate, and beverage products should have form-specific rules. Child-resistant packaging and restrictions on child-appealing design are justified. Advertising should not target minors, make unsupported medical claims, or use behavioral data to identify heavy or vulnerable users. National rules should permit comparison and state experimentation rather than freeze today's product market.

Tax should be high enough to fund regulation, public health, treatment, research, and record repair, but not so high that it preserves a dominant illicit market. A potency-sensitive component may be more aligned with risk than price alone, though measurement and product substitution must be evaluated. Revenue forecasts should not create a public dependence on increasing consumption.

Federal law should define impairment offenses by unsafe operation and validated evidence, not by a biological number copied from alcohol without equivalent scientific grounding. Train drug- recognition and roadside practice, fund better impairment research, require confirmatory evidence where feasible, and preserve challenge. Employers may regulate on-duty impairment and safety- sensitive work; an old metabolite or lawful off-duty use should not automatically prove impairment.

Adults should be allowed limited home cultivation subject to plant, safety, nuisance, and transfer rules. Small growers and social-equity applicants need a viable licensing route, but identity-based preference cannot substitute for access to capital, premises, technical compliance, and markets. Antitrust and license concentration review should prevent a few firms from converting legalization into an addiction-optimization industry.

Federal simple-possession convictions should be automatically expunged or sealed through a process that does not require a lawyer. Sentences based solely on conduct made lawful should be reviewed. Congress should fund state automation and data correction. Relief does not extend to violence, coercion, impaired driving, sales to minors, or independent trafficking conduct merely because the case also involved cannabis.

Decriminalize possession without commercializing lethal drugs

Possession of a small quantity for personal use should not produce jail or a criminal record. Police may confiscate the substance, address immediate unsafe conduct, identify an overdose or medical risk, and issue a civil referral. The quantity threshold should be drug specific and based on ordinary personal-use patterns, potency, packaging, evidence of sale, and uncertainty. It should not be a universal gram number that treats a lethal fentanyl mixture like cannabis or uses quantity alone to prove trafficking.

Decriminalization is not a legal retail market. The party opposes commercial sale of fentanyl, methamphetamine, heroin, cocaine, and similarly high-risk drugs outside legitimate medical and research channels. Supply remains illegal. Manufacturing, importation, large-scale distribution, adulteration, counterfeit pills, coercive dealing, sales to minors, and violence remain criminal, with penalties proportionate to culpability and actual risk.

The civil response should be modest enough not to recreate criminalization through debt. A first possession event should generate confiscation, clear risk information, naloxone where relevant, and an offered assessment. A person with signs of a substance-use disorder should receive a scheduled care contact, not a phone list. Repeated possession can trigger assertive outreach and a civil hearing focused on connection to care. Failure to recover is not contempt. Detention requires an independent lawful basis, such as a specific dangerous act or the grave-risk standard in HEALTH-05.

Oregon's experience warns against presenting decriminalization as self-executing. A citation and hotline cannot substitute for visible treatment capacity, street outreach, rules against public use, and public confidence. A state may revise thresholds or process when implementation fails. The principled line remains between personal possession and conduct that injures or materially endangers other people.

Treatment must function as a service

In 2024, SAMHSA estimated that 52.6 million people age 12 or older needed substance-use treatment, while 10.2 million received treatment. Only about one in five people classified as needing it received it. These survey categories have definitions and limitations, but the service gap is too large for “refer to treatment” to be a serious legal alternative.

HEALTH-05 establishes the Behavioral Health Care Clock. Applied here, an overdose or acute crisis requires same-day assessment and a warm handoff, with follow-up within 72 hours. Urgent addiction care should be available within seven days and routine care within 30. If a network misses the clock, publicly financed coverage should pay for a qualified alternative.

Evidence-based care must include medications for opioid-use disorder. CDC states that medication treatment is associated with reduced overdose and overall mortality and that detoxification alone is not recommended because it increases risks of resumed use, overdose, and death. Treatment also includes medications for alcohol-use disorder, counseling, contingency management under validated protocols, infectious-disease care, pain care, psychiatric care, family support, recovery housing, peer work, education, and employment.

No single recovery ideology should control public access. Abstinence can be a person's goal and a program's supported pathway. Medication is not a moral failure. Harm reduction is not a complete life plan. Relapse is a clinical and safety event, not proof that care is futile. Public programs should measure survival, reduced dangerous use, treatment retention, health, housing, relationships, learning, employment, and the patient's own durable goals.

Overdose and infectious-disease prevention

Naloxone rapidly reverses opioid overdose, has no abuse potential, and is available in approved over-the-counter forms. It should be stocked in schools consistent with age and risk, libraries, shelters, transit, bars and venues, workplaces, correctional release, police and fire vehicles, colleges, treatment sites, and other places selected through local overdose data. Training should be brief, multilingual, and paired with a call to emergency services because reversal can wear off or require further care.

Good Samaritan protection should cover good-faith calls for overdose aid and possession discovered through the call, while preserving enforcement for violence, weapons offenses, trafficking evidence independent of the request, and harm to a child or vulnerable person. People should not weigh a friend's breathing against the risk of a possession arrest.

Sterile syringe services, safe disposal, vaccination, HIV and hepatitis testing, wound care, naloxone, drug checking, and treatment linkage reduce specific harms and create repeated contact with care. Programs need site management, litter response, security, hours, neighborhood communication, and transparent outcomes. “Harm reduction” cannot mean that nearby residents absorb discarded equipment, dealing, threats, or blocked access.

Supervised-consumption or overdose-prevention sites deserve bounded local pilots, not a national claim that their population effect is settled. Staff can reverse on-site overdoses and connect people to services. Evidence on population-level mortality is mixed and context dependent, and a federal review has called for more rigorous research. A pilot should operate only under clear legal authority, never supply illegal drugs, maintain emergency response, prohibit on-site dealing, manage the exterior, publish service and neighborhood measures, and close or change if it concentrates harm without sufficient benefit.

Public-order rules should govern conduct

Decriminalizing possession does not create a right to consume anywhere. Cities may enforce proportionate rules against use on transit, in schools and playgrounds, in doorways, near treatment and shelter entrances, while driving, or in another place where intoxication or smoke materially burdens others. Police may intervene against violence, threats, obstruction, dangerous fire, discarded needles, harassment, and impaired operation regardless of whether addiction contributes.

Enforcement should target the conduct and offer a usable off-street or clinical path where the conduct is tied to need. A warning, relocation, transport, citation, or arrest may be appropriate depending on danger and repetition. Unpayable fines and serial displacement can reproduce the harm of criminal possession without restoring order. A severe, persistent inability to meet basic needs may qualify for the due-process-protected intervention described in HEALTH-05; diagnosis alone does not.

Public order and compassion reinforce each other when duties are real. Residents should not be told that fear, smoke, obstruction, or open intoxication is the price of empathy. A person with addiction should not be told that jail is treatment because no other institution answered. The government owes a place where help can occur and a rule that keeps shared space shared.

Psychedelics: accelerate learning, resist hype

Psychedelic compounds show promise for some psychiatric and substance-use conditions. FDA has issued guidance for clinical investigations and emphasizes trial design, safety monitoring, psychotherapy's role, dose response, expectancy and blinding problems, abuse potential, and durability. That is a reason to make rigorous research easier and faster. It is not evidence that every retreat, facilitator, microdose product, or broad claim is safe and effective.

Congress and agencies should simplify research registration, expand public funding, support active comparators and long follow-up, collect adverse events, and train qualified investigators. FDA should apply ordinary safety and effectiveness standards while adapting trial design to the compounds' obvious psychoactive effects. Data should distinguish the drug, preparation, therapeutic support, population, dose, setting, and outcome.

States may run controlled clinical or service pilots within federal waivers or statutory authority. They should license sites and facilitators, test product, screen for contraindications, require informed consent, protect participants from sexual and financial exploitation, ensure emergency plans, prohibit guaranteed cures, report adverse events, and define an evaluation and sunset. General retail sale or a lightly regulated wellness market should wait for evidence and a product- specific risk model.

The coherent line

The position is not permissive toward every drug or punitive toward every user. It asks four questions. Is the person exercising adult autonomy or losing agency to addiction? Is the conduct private or imposing danger and disorder on others? Is the actor possessing for use or profiting from predatory supply? Does the intervention have evidence, capacity, and a revision rule?

Those questions yield firm answers. Legal adult cannabis: yes, with rules. A criminal record for a small possession amount: no. A commercial fentanyl market: no. Naloxone and medications: yes. Open-air dealing and persistent public use: enforce. Psychedelic research: accelerate. Psychedelic hype sold as medicine: restrain. Treatment coerced because it is cheaper than care: reject. Treatment offered as an immediate credible alternative: build it.

Regulate risk. Treat addiction. Punish predation. Stop making possession the center of drug policy.

That sequence is also an accountability rule. Regulators must answer for the legal market, clinicians and payers for treatment access, police and prosecutors for proportional enforcement, and pilot operators for participant and neighborhood effects. Moving responsibility from one institution to another never makes the public duty disappear.